Intensive Prevention Program After Myocardial Infarction

Overview

It is unknown, if a modern prevention program, including intense nurse-coordinated education sessions, regular telephone contacts and a telephone hotline for 12 months, significantly reduces cardiovascular risk factors, clinical events and quality of life in myocardial infarction patients compared to usual care. Furthermore, actually no data on the additional effects and the feasibility of longterm telemetric care of cardiovascular risk factors exist. The primary hypothesis to be tested is that an intensive longterm prevention program compared to the standard of medical care, will achieve better risk factor control and consecutively less clinical adverse events in patients after myocardial infarctions. The study endpoints will be evaluated after 12 months and during long-term course (after 24 months = one year after termination of the prevention program). In a substudy the effects of short reinterventions ("Prevention Boosts") during long-term course are tested (IPP Prevention Boost Study). Patients with at least one insufficiently controlled risk factor at 24-months visit are randomly assigned to a short (2-month) reintervention vs. no reintervention. The effects of the reinterventions on risk factor control are evaluated after 36 months. A further substudy focusing on young patients <= 45 years of age at time of MI (IPP-Y = IPP in the Young) was added after completion of the pilot IPP study. In this study we focus on the prevention program in young MI-patients. A retrospective analysis of individual genetic risk (assessed by genetic risk scores) in the young patients is included in this substudy.

Full Title of Study: “Intensive Longterm Prevention Program After Myocardial Infarction in Northwest Germany”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: March 2020

Interventions

  • Behavioral: Intensive Prevention Program
    • “Study nurse”-coordinated education sessions, telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available).
  • Other: Standard medical and interventional therapy
    • Medical and interventional therapy following the standard of care.

Arms, Groups and Cohorts

  • Experimental: Intensive prevention program
    • Standard care with respect to medical and interventional therapy plus intensive prevention program with “study nurse”-coordinated education sessions, regular telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available).
  • Other: Usual care
    • Standard care with respect to medical and interventional therapy.

Clinical Trial Outcome Measures

Primary Measures

  • Prevention score (point score of cardiovascular risk factors)
    • Time Frame: 24 months
  • Prevention success
    • Time Frame: 24 months
    • Improvement of one of the risk factors LDL-cholesterol, physical inactivity, smoking without deterioration of another (primary endpoint for IPP-Y = substudy on young MI-patients <= 45 years that was added after completion of the pilot study)

Secondary Measures

  • Combined endpoint of clinical adverse events
    • Time Frame: 24 months
  • Adherence to prognostic relevant medication after myocardial infarction
    • Time Frame: 24 months

Participating in This Clinical Trial

Inclusion Criteria

Hospitalisation due to myocardial infarction (ST-elevation or non-ST-elevation myocardial infarction) Exclusion Criteria:

i) Hemodynamically significant valvular heart disease (> NYHA class II) or inborn cardiac malformations. ii) Cardiomyopathy associated with hemodynamic obstruction, pregnancy or myocarditis. iii) Exercise limitations due to clinical conditions not related to CAD. iv) Any major non-cardiac condition that would adversely effect survival during the duration of the study. v) Patients unlikely to comply to the study treatment and the follow-up visits. vi) Pregnancy (all pre-menopausal females should have a negative serum pregnancy test). vii) Inability of cooperation with the protocol, including longterm follow-up. viii) Patient refusal or inability to give informed consent. ix) Refusal of the patient's physician regarding trial participation of the patient. x) Chronic drug or alcohol abuse.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Herzzentrum Bremen
  • Collaborator
    • Oldenburger Forschungs- und Entwicklungsinstitut für Informatik (OFFIS).
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.